[Protective effect of alpha beta-blockers on hypertensive target-organ damage].
Kai
Hisashi
H
Third Department of Internal Medicine, Kurume University School of Medicine.
Imaizumi
Tsutomu
T
D000310:Adrenal Gland Neoplasms / Q000150:complications; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050260:Carbohydrate Metabolism; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007741:Labetalol / Q000494:pharmacology / Q000627:therapeutic use*; D050356:Lipid Metabolism; D010673:Pheochromocytoma / Q000150:complications; D011379:Prognosis
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D007741:Labetalol